Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

ABLYNX (D) : RECEIVES FURTHER MILESTONE PAYMENTS OF EUR3 MILLION AS PART OF ITS STRATEGIC ALLIANCE WITH BOEHRINGER INGELHEIM

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/01/2010 | 07:05am CEST




  GHENT, Belgium, 1 October 2010 - Ablynx [Euronext Brussels: ABLX] today
announced that it will receive further milestone payments totalling EUR3 million
from Boehringer Ingelheim, triggered as part of its strategic alliance for the
development and commercialisation of Nanobodies(®). Ablynx has now earned a
total of EUR12 million in milestone payments as part of this agreement.

Ablynx and Boehringer Ingelheim entered into an agreement in September 2007 to
collaborate on the discovery, development and commercialisation of up to 10
different Nanobody therapeutics across a range of areas including for example
immunology, oncology and respiratory diseases. The agreement would allow
potential milestone payments of up to EUR125 million for each Nanobody developed
as well as undisclosed royalties to Ablynx. Boehringer Ingelheim is exclusively
responsible for the development, manufacture and commercialisation of any
products resulting from the collaboration. Ablynx retains certain co-promotion
rights in Europe.

Dr Edwin Moses, CEO and Chairman of Ablynx, said: "We are pleased that yet
another Nanobody programme has reached this contractual milestone. The Nanobody
platform continues to deliver across therapeutic areas and also for complex
targets."

-ends-

 About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com

Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused
on the discovery and development of Nanobodies, a novel class of therapeutic
proteins based on single-domain antibody fragments, for a range of serious and
life-threatening human diseases. The Company currently has over 250 employees.
Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November
2007 and raised EUR50 million through an SPO in March 2010.

Ablynx is developing a portfolio of Nanobody-based therapeutics in a number of
major disease areas, including inflammation, thrombosis, oncology and
Alzheimer's disease. Ablynx now has over 25 programmes in its therapeutic
pipeline including four Nanobodies in clinical development. So far, Nanobodies
have been successfully generated against more than 220 different protein targets
including several complex targets such as chemokines, GPCRs, ion channels and
viruses, which are typically very difficult to address with conventional
monoclonal antibodies.



For more information, please contact Ablynx:

Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: [email protected]

Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: [email protected]



[HUG#1448178]





Cpmplete version of the press release:
http://hugin.info/137912/R/1448178/390562.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Ablynx via Thomson Reuters ONE

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABLYNX
05/25ABLYNX : Notice in relation to the convertible bonds due may 2020
GL
05/21ABLYNX : Publication in accordance with article 14 of the belgian law of 2 may 2..
GL
05/17ABLYNX : 17/05/2018 ablynx announces warrant exercise
PU
05/17ABLYNX : Announces warrant exercise
GL
05/17ABLYNX : Announces warrant exercise
AQ
05/17ABLYNX : Threshold crossings
CO
05/14ABLYNX NV : quaterly earnings release
05/14ABLYNX : 14/05/2018 sanofi and ablynx announce the successful results of the ini..
PU
05/14Sanofi-Ablynx Deal Goes Ahead
DJ
05/14ABLYNX : Sanofi and ablynx announce the successful results of the initial tender..
GL
More news
News from SeekingAlpha
05/02YOUR DAILY PHARMA SCOOP : KPTI Data, Allergan Write-Off, Celgene Down On Delay 
04/30Ablynx completes enrollment in mid-stage study of ALX-0171 in RSV 
03/26Ablynx's vobarilizumab flunks mid-stage lupus study 
03/02Mid-stage study underway in Japan for Ablynx ALX-0171 in RSV 
02/22Ablynx NV reports FY results 
Financials (€)
Sales 2018 64,5 M
EBIT 2018 -43,8 M
Net income 2018 -60,3 M
Finance 2018 28,0 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 52,1x
EV / Sales 2019 20,3x
Capitalization 3 390 M
Chart ABLYNX
Duration : Period :
Ablynx Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Technical analysis trends ABLYNX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 44,4 €
Spread / Average Target -1,2%
EPS Revisions
Managers
NameTitle
Edwin Moses Chief Executive Officer & Executive Director
Russell G. Greig Chairman
Wim Ottevaere Chief Financial Officer
Robert K. Zeldin Chief Medical Officer
Robert Freisen Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABLYNX116.99%3 950
CELLTRION, INC.--.--%32 036
IQVIA HOLDINGS INC2.66%20 818
LONZA GROUP2.20%20 226
INCYTE CORPORATION-29.61%14 505
NEKTAR THERAPEUTICS33.89%13 705